Celebrating One Year of Spot On CML

Celebrating One Year of Spot On CML

The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.

These tests are critically important because a confirmed diagnosis is required for a patient to begin receiving free treatment through our donation programs – and access to treatment is access to life.

We extend our deepest thanks to the dedicated team at Fred Hutch and the hundreds of physicians and nurses around the world who work tirelessly to support their patients. Thanks to your efforts, we not only met but exceeded our initial goal – testing one new patient per day for an entire year.

Here’s how the patient numbers break down by country:

  • Bhutan – 5
  • Cambodia – 2
  • Cote d’Ivoire – 10
  • East Timor – 3
  • Fiji – 5
  • Honduras – 40
  • Kenya – 7
  • Mexico – 30
  • Mongolia – 21
  • Nepal – 95
  • Niger – 18
  • Nigeria – 10
  • Philippines – 17
  • Tajikistan – 50
  • Uganda – 58

About Spot On CML 

Launched in 2017, Spot On CML is a groundbreaking collaboration between The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries. The initiative utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2031

    Building on two decades of progress, Max’s ambitious goal will expand its proven, patient-centered model that has already helped more than 100,000 people access treatment Commitment will enhance local health system capabilities to deliver innovative and generic medicines, diagnostics, and treatment in more than 80 low- and middle-income countries Alongside this commitment, Max and Novartis sign….

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.

  • The Max Foundation & Esperantra Forge a Deeper Collaboration to Benefit Leukemia Patients in Peru

    The Max Foundation & Esperantra Forge a Deeper Collaboration to Benefit Leukemia Patients in Peru

    The Max Foundation and partner NGO Esperantra are pleased to announce they have signed a new MOU that will help patients in Peru gain access to treatment.